Department of Preventive Cardiology, Oslo University Hospital Ullevål, Oslo, Norway.
Nicotine Tob Res. 2011 Jan;13(1):1-6. doi: 10.1093/ntr/ntq191. Epub 2010 Nov 1.
Dianicline is a α4β2 nicotinic acetylcholine receptor partial agonist, a class of drugs that includes varenicline and cytisine. Varenicline is efficacious for smoking cessation, while cytisine has not been studied systematically. The efficacy of dianicline has not been previously tested in an adequately powered study.
In a randomized, double-blind, parallel group placebo-controlled trial, 602 generally healthy cigarette smokers were assigned to dianicline (n = 300) or placebo (n = 302) for 7 weeks followed by a 19-week off drug follow-up period.
Exhaled carbon monoxide and cotinine-confirmed continuous abstinence rates for Weeks 4-7 were 24.0% for dianicline versus 20.5% for placebo (odds ratio 1.22; 95% CI, 0.83-1.80; p = .307). For Weeks 4-26, the abstinence rates were 16.7% for dianicline versus 13.9% for placebo (odds ratio 1.24; 95% CI, 0.79-1.93; p = .366). Craving for a cigarettes was reduced by dianicline compared with placebo after 7 weeks (p = .0175). Nicotine withdrawal symptoms measured by the Hughes and Hatsukami Minnesota Withdrawal Scale were lower for dianicline compared with placebo in the first 3 weeks of treatment during which time quit rates were also higher in the dianicline-treated group.
Dianicline did not increase cigarette smoking abstinence rates beyond the initial phase of treatment. However, self-reported craving and nicotine withdrawal symptoms were reduced.
Dianicline 是一种 α4β2 烟碱型乙酰胆碱受体部分激动剂，属于包括伐伦克林和烟碱的药物类别。伐伦克林对戒烟有效，而烟碱尚未系统研究。Dianicline 的疗效以前没有在充分有力的研究中进行过测试。
在一项随机、双盲、平行组安慰剂对照试验中，602 名一般健康的吸烟者被分配到 Dianicline（n = 300）或安慰剂（n = 302）组，治疗 7 周，然后停药 19 周随访期。
第 4-7 周呼气一氧化碳和可替宁证实的持续戒烟率为 Dianicline 组 24.0%，安慰剂组 20.5%（优势比 1.22；95%CI，0.83-1.80；p =.307）。第 4-26 周，Dianicline 组的戒烟率为 16.7%，安慰剂组为 13.9%（优势比 1.24；95%CI，0.79-1.93；p =.366）。与安慰剂相比，Dianicline 治疗 7 周后可降低对香烟的渴望（p =.0175）。使用 Hughes 和 Hatsukami 明尼苏达州戒断量表测量的尼古丁戒断症状在 Dianicline 治疗的前 3 周内低于安慰剂，在此期间 Dianicline 治疗组的戒烟率也更高。
Dianicline 并没有提高戒烟率超过治疗的初始阶段。然而，自我报告的渴望和尼古丁戒断症状有所减轻。
